Crossmark

Continuous versus intermittent short-acting β2-agonists nebulization as first-line therapy in hospitalized children with severe asthma exacerbation: a propensity score matching analysis

Crossref DOI link: https://doi.org/10.1186/s40733-020-00059-5

Published Online: 2020-07-02

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kulalert, Prapasri

Phinyo, Phichayut http://orcid.org/0000-0002-8543-6254
Patumanond, Jayanton

Smathakanee, Chutima

Chuenjit, Wantida

Nanthapisal, Sira
License Information

Text and Data Mining valid from 2020-07-02

Version of Record valid from 2020-07-02
More Information

Article History

Received: 5 May 2020

Accepted: 21 June 2020

First Online: 2 July 2020

Ethics approval and consent to participate

: The Institutional Review Board and the Ethics Committee of Hat Yai Hospital (protocol number 33/2561) and the Faculty of Medicine, Thammasat University (MTU-EC-ES-0-061/61) approved the study protocol. The requirement for informed consent was waived as the data were retrospectively collected and were anonymous.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below